Huntington’s Disease Market Size-By Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
Global Huntington’s Disease Market Overview
According to SPER Market Research, the Global Huntington’s Disease Market is estimated to reach USD 2.65 billion by 2032 with a CAGR of 19.83%. The global market for Huntington's disease is expanding as a result of significant R&D expenditures for the creation of novel products, research partnerships, and the high prevalence of HD in western nations. An uncommon hereditary neurological disorder that affects multiple generations, is Huntington's disease. People in adult age are affected, which limits their ability to work, take care of their families, and finally finish everyday duties.
Impact of COVID-19 on the Global Huntington’s Disease Market
The worldwide COVID-19, however, caused a slowdown in the therapy market for Huntington's disease. Antidepressants, antipsychotics, and anticonvulsants were among the off-label medications sold by online pharmacies during the epidemic to treat HD symptoms. Clinical experiments during the COVID-19 pandemic were halted because to the government shutdown.
Scope of the report:
Market size available for the years 2019-2032
Base year considered 2021
Forecast Period 2022-2032
Segments Covered By Treatment
Regions Covered Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
Companies Covered Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin,
Global Huntington’s Disease Market Segmentation:
By Treatment:Based on the Treatment, Global Huntington’s Disease Market is segmented as; Symptomatic treatment, Disease-modifying therapies.
By Region:Due to improved reimbursement infrastructure and the significant financial burden of HD in the United States and Canada, North America, which accounted for the greatest revenue share in previous year, is anticipated to dominate the market throughout the forecast period.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER’s internal database
- 2.1.4 Premium insight from KOL’s
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Global Huntington’s Disease Market
- 5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER’S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
- 6. Competitive Landscape
- 6.1 Global Huntington’s Disease Manufacturing Base Distribution, Sales Area, Product Type
- 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Huntington’s Disease Market
- 7. Global Huntington’s Disease Market, By Treatment, 2019-2032 (USD Million)
- 7.1 Symptomatic treatment
- 7.2 Disease-modifying therapies
- 8. Global Huntington’s Disease Market, By Region, 2019-2032 (USD Million)
- 8.1 Global Huntington’s Disease Size and Market Share by Region (2019-2025)
- 8.2 Global Huntington’s Disease Size and Market Share by Region (2026-2032)
- 8.3 Asia-Pacific
- 8.3.1 Australia
- 8.3.2 China
- 8.3.3 India
- 8.3.4 Japan
- 8.3.5 South Korea
- 8.3.6 Rest of Asia-Pacific
- 8.4 Europe
- 8.4.1 France
- 8.4.2 Germany
- 8.4.3 Italy
- 8.4.4 Spain
- 8.4.5 United Kingdom
- 8.4.6 Rest of Europe
- 8.5 Middle East and Africa
- 8.5.1 Kingdom of Saudi Arabia
- 8.5.2 United Arab Emirates
- 8.5.3 Rest of Middle East & Africa
- 8.6 North America
- 8.6.1 Canada
- 8.6.2 Mexico
- 8.6.3 United States
- 8.7 Latin America
- 8.7.1 Argentina
- 8.7.2 Brazil
- 8.7.3 Rest of Latin America
- 9. Company Profiles
- 9.1 Annexon Biosciences
- 9.1.1 Company details
- 9.1.2 Financial outlook
- 9.1.3 Product summary
- 9.1.4 Recent developments
- 9.2 Bausch Health Companies Inc.
- 9.2.1 Company details
- 9.2.2 Financial outlook
- 9.2.3 Product summary
- 9.2.4 Recent developments
- 9.3 Dr. Reddy's Laboratories Ltd
- 9.3.1 Company details
- 9.3.2 Financial outlook
- 9.3.3 Product summary
- 9.3.4 Recent developments
- 9.4 Eli Lilly And Company
- 9.4.1 Company details
- 9.4.2 Financial outlook
- 9.4.3 Product summary
- 9.4.4 Recent developments
- 9.5 H. Lundbeck A/S
- 9.5.1 Company details
- 9.5.2 Financial outlook
- 9.5.3 Product summary
- 9.5.4 Recent developments
- 9.6 Hetero
- 9.6.1 Company details
- 9.6.2 Financial outlook
- 9.6.3 Product summary
- 9.6.4 Recent developments
- 9.7 Hikma Pharmaceuticals PLC
- 9.7.1 Company details
- 9.7.2 Financial outlook
- 9.7.3 Product summary
- 9.7.4 Recent developments
- 9.8 Lupin
- 9.8.1 Company details
- 9.8.2 Financial outlook
- 9.8.3 Product summary
- 9.8.4 Recent developments
- 9.9 Medesis pharma SA
- 9.9.1 Company details
- 9.9.2 Financial outlook
- 9.9.3 Product summary
- 9.9.4 Recent developments
- 9.10 Mitochon Pharmaceuticals
- 9.10.1 Company details
- 9.10.2 Financial outlook
- 9.10.3 Product summary
- 9.10.4 Recent developments
- 9.11 Neurocrine bioscience Inc.
- 9.11.1 Company details
- 9.11.2 Financial outlook
- 9.11.3 Product summary
- 9.11.4 Recent developments
- 9.12 Novartis
- 9.12.1 Company details
- 9.12.2 Financial outlook
- 9.12.3 Product summary
- 9.12.4 Recent developments
- 9.13 PTC Therapeutics, Inc.
- 9.13.1 Company details
- 9.13.2 Financial outlook
- 9.13.3 Product summary
- 9.13.4 Recent developments
- 9.14 SOM Biotech
- 9.14.1 Company details
- 9.14.2 Financial outlook
- 9.14.3 Product summary
- 9.14.4 Recent developments
- 9.15 Sun Pharmaceutical Industries Ltd.
- 9.15.1 Company details
- 9.15.2 Financial outlook
- 9.15.3 Product summary
- 9.15.4 Recent developments
- 9.16 Teva Pharmaceutical Industries Ltd.
- 9.16.1 Company details
- 9.16.2 Financial outlook
- 9.16.3 Product summary
- 9.16.4 Recent developments
- 9.17 UniQure
- 9.17.1 Company details
- 9.17.2 Financial outlook
- 9.17.3 Product summary
- 9.17.4 Recent developments
- 9.18 Vaccinex, Inc.
- 9.18.1 Company details
- 9.18.2 Financial outlook
- 9.18.3 Product summary
- 9.18.4 Recent developments
- 10. List of Abbreviations
- 11. Reference Links
- 12. Conclusion
- 13. Research Scope
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook